Alexium secures R&D partnership, purchase order

|

Published 19-OCT-2015 15:57 P.M.

|

1 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Manufacturing player Alexium (ASX:AJX) has secured an ongoing R&D partnership with one of the larger players in the flame retardant industry – just as it starts to diversify from the textile industry.

The ASX-listed AJX told the market this morning that it has secured an ongoing partnership with New York Stock Exchange-listed Israel Chemicals Limited (ICL) through a South Carolina government initiative.

The state government is putting in $232,000 into the partnership for AJX, with the research team reportedly looking at the development of flame retardant products for a $150 million military and specialty fabric industries.

The continuation of the partnership with ICL is a boon, with the Israeli company a major force in the industry with sales reaching $6.1 billion last year.

It also comes hot on the heel of news that it had secured a purchase order from the plastics market, a market which AJX had not been playing in before.

AJX told investors late last week that it had received a purchase order from the plastics market, although the size and potential value of the order were not disclosed.

It represents a diversification from AJX which had focused on the textile and military industries previously.

AJX has estimated the flame retardant chemical market outside of textiles to be worth $6.6 billion by 2019.

It also said that it had been in discussions with other companies about scale-up and potential purchase orders into the future.

Meanwhile, it also confirmed that it has won a second major US bedding client, bringing expected revenue from the two customers up to $6.8 million per year.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X